Skip to content
Study details
Enrolling now

Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)
NCT IDNCT06096857ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

240

Study length

about 1.2 years

Ages

2–100

Locations

1 site in MD

About this study

Researchers are testing a skin treatment containing R. mucosa and ground cardamom seeds for people with atopic dermatitis (eczema). The trial will last about 7 months, involving remote visits and questionnaires to assess the effect of this treatment on participants' skin condition.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Placebo (sucrose)
  • 2.Take Roseomonas mucosa (RSM2015) and Cardamom seeds
PhasePhase 2
Primary goalTo determine if R mucosa combined with ground cardamom seeds can improve symptoms of AD in patients aged 2 and older, 14 weeks after treatment discontinuation

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: To determine if R mucosa combined with ground cardamom seeds can improve symptoms of AD in patients aged 2 and older, 14 weeks after treatment discontinuation.

Secondary: To determine if R mucosa combined with ground cardamom seeds can improve symptoms of AD in patients aged 2 and older, during active treatment as well as 7 weeks after treatment discontinuation.

Body systems

Dermatology